Drug Puts A $750,000 ‘Price Tag On Life’

KHN Original

The high cost of Spinraza, a new and promising treatment for spinal muscular atrophy, highlights how the cost-benefit analysis insurers use to make drug coverage decisions plays out in human terms.

Take Our Quiz To Test Your Wits On Aging

KHN Original

As we get older, it helps to tickle the noggin’ with trivia. Here’s a pop quiz to see what you have learned as a regular reader of Kaiser Health News.